Troriluzole + Placebo + Troriluzole
Phase 2/3CompletedDevelopment Stage
Spinocerebellar Ataxias
Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2, Spinocerebellar Ataxia Genotype Type 3, Spinocerebellar Ataxia Genotype Type 6, Spinocerebellar Ataxia Genotype Type 7, Spinocerebellar Ataxia Genotype Type 8, Spinocerebellar Ataxia Genotype Type 10
Dec 15, 2016 → Sep 20, 2024
About Troriluzole + Placebo + Troriluzole
Troriluzole + Placebo + Troriluzole is a phase 2/3 stage product being developed by Biohaven for Spinocerebellar Ataxias. The current trial status is completed. This product is registered under clinical trial identifier NCT02960893. Target conditions include Spinocerebellar Ataxias, Spinocerebellar Ataxia Genotype Type 1, Spinocerebellar Ataxia Genotype Type 2.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02960893 | Phase 2/3 | Completed |
Competing Products
15 competing products in Spinocerebellar Ataxias
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373 + Placebo | Kissei Pharmaceutical | Phase 3 | 76 |
| KPS-0373 | Kissei Pharmaceutical | Phase 2 | 51 |
| KPS-0373, High dose + KPS-0373, Low dose | Kissei Pharmaceutical | Phase 3 | 76 |
| varenicline + placebo | Pfizer | Phase 2 | 51 |
| BIIB132 + BIIB132-Matching Placebo | Biogen | Phase 1 | 30 |
| IVIG | Baxter | Phase 2 | 49 |
| Intravenous Immune Globulin (IVIG) | Baxter | Phase 1 | 30 |
| ARO-ATXN2 Injection + Placebo | Arrowhead Pharmaceuticals | Phase 1 | 30 |
| BHV-4157 | Biohaven | Pre-clinical | 18 |
| troriluzole + Placebo | Biohaven | Phase 3 | 72 |